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Abstract
Purpose The aims of this study were to characterize the
concentration–time course of cladribine (CdA) and its main
metabolite 2-chloroadenine (CAde), estimate interindivid-
ual variability in pharmacokinetics (PK), and identify
covariates explaining variability in the PK of CdA.
Methods This population PK analysis was based on the
combined dataset from four clinical studies in patients with
multiple sclerosis (MS): three phase I studies, including
one food and one drug–drug interaction study, and one
phase III clinical study. Plasma and urine concentration
data of CdA and CAde were modeled simultaneously.
Results The analysis comprised a total of 2619 CdA and
CAde plasma and urine concentration observations from
173 patients with MS who received an intravenous infusion
or oral tablet doses of CdA as a single agent or in com-
bination with interferon (IFN) b-1a. CdA PK data were
best described by a three-compartment model, while a one-
compartment model best described the PK of CAde. CdA
renal clearance (CLR) was correlated with creatinine
clearance (CLCR), predicting a decrease in the total
clearance of 19%, 30% and 40% for patients with mild
(CLCR = 65 ml/min), moderate (CLCR = 40 ml/min) and
severe (CLCR = 20 ml/min) renal impairment, respec-
tively. Food decreased the extent of CdA absorption by
11.2% and caused an absorption delay. Coadministration
with IFNb-1a was found to increase non-CLR (CLNR) by
21%, resulting in an increase of 11% in total clearance.
Conclusions Both CdA and CAde displayed linear PK
after intravenous and oral administration of CdA, with CdA
renal function depending on CLCR.
Trial registration number for study 25643: NCT00213135.
Key Points
The pharmacokinetics of cladribine (CdA) and its
main metabolite 2-chloroadenine (CAde) in patients
with multiple sclerosis were described after
intravenous and oral administration of CdA.
Both renal and non-renal clearances were estimated
for CdA and CAde.
Covariate effects of food on CdA absorption and of
coadministration of interferon b-1a on non-renal
clearance were characterized.
1 Introduction
Cladribine (2-chloro-20-deoxyadenosine; CdA), is a syn-
thetic deoxyadenosine analog that is activated by intra-
cellular phosphorylation in specific cell types, resulting in a
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targeted reduction of circulating lymphocytes [1].
Injectable formulations of CdA have been approved in
many countries for the treatment of hematological malig-
nancies [2]. It was hypothesized that CdA may have ben-
eficial effects in the treatment of autoimmune disorders
such as multiple sclerosis (MS) due to its selective lym-
phocyte-reducing properties [2]. This led to the develop-
ment of an oral formulation of CdA, cladribine tablets, for
investigation in relapsing–remitting MS. Cladribine tablets
demonstrated significant efficacy compared with placebo
on clinical and neuroimaging measures in the large, phase
III, 96-week CLARITY (CLAdRIbine Tablets Treating MS
OrallY) study [3]. The development program for cladribine
tablets, as well as long-term follow-up of patients exposed
to cladribine tablets, is ongoing.
The population pharmacokinetics (PK) of CdA have
been previously studied in patients with malignancies after
administration of parenteral, intravenous and oral solutions
[4]. We studied the population PK in patients with MS
because physiological differences related to disease
pathology in patients with malignancies and those with MS
could lead to different kinetic and metabolic behavior for
CdA. In addition, the dosing level and schedule and drug
formulation that were proposed for use in MS are different
from those routinely used in the oncology setting. Data
from the main metabolite of CdA, 2-chloroadenine (CAde),
were also available for this analysis; it has been docu-
mented that metabolite data can provide additional infor-
mation about the kinetics of the parent drug itself [5].
The overall objective of our analysis was to assess the
population PK of CdA and its main metabolite, CAde, after
oral tablet administration in patients with relapsing–
remitting MS. The specific aims of the analysis included
quantifying different routes of CdA elimination (renal and
non-renal); assessing the effect of food on CdA absorption
and bioavailability; and assessing potential drug–drug
interactions of CdA with interferon (IFN) b-1a.
2 Methods
2.1 Clinical Trials
This population PK analysis evaluated data obtained from
four clinical studies of CdA (studies 25803, 26127, 26486
and 25643 [CLARITY; trial registration number:
NCT00213135]).
Study 25803 was a phase I, open-label, randomized,
two-period, two-sequence crossover study investigating the
PK of CdA and its metabolites following the administration
of a single oral tablet and a single intravenous dose in
patients with MS. Sixteen patients were enrolled this study.
Patients received CdA 3 mg intravenously as a single 1-h
infusion or as a single 10 mg tablet, with a minimum
10-day washout between each treatment. In each treatment
period, blood and urine samples were collected for the
evaluation of CdA and CAde, pre-dose (within 5–30 min
before dosing) and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24,
36, 48, 72, 96 and 120 h post-dose. Urine was collected
pre-dose (within 2 h before dosing) and at 0–4, 4–8, 8–12,
12–24, 24–48 and 48–72 h post-dose.
Study 26127 was a phase I, randomized, two-way,
crossover study investigating the effects of food on the PK
of CdA administered as oral tablets to patients with MS (16
patients).
Patients were randomized (1:1) to one of two treatment
sequences. One group received the treatments in the ‘fed
then fasted’ sequence, and the other group received the
treatment in the ‘fasted then fed’ sequence. Each treatment
consisted of a single 10 mg cladribine tablet. In both
treatment periods, blood samples for the assessment of
CdA concentration were collected pre-dose (within
5–30 min prior to dosing), and at 0.5, 1, 1.5, 2, 3, 4, 6, 8,
12, 16, 24, 36, 48 and 72 h post-dose.
Study 26486 was an open-label, multiple-dose study
assessing the effects of oral cladribine tablets on the PK of
subcutaneous IFNb-1a (Rebif, Merck KGaA, Darmstadt,
Germany) and vice versa, as well as the safety of combi-
nation treatment in patients with MS. Sixteen patients
received one or two 10 mg cladribine tablets administered
once-daily for 5 consecutive days (days 1–5). After at least
2 days, patients received IFNb-1a as follows: 8.8 lg three
times weekly (days 7–18; six doses), then 22 lg three
times weekly (days 21–32; six doses), followed by 44 lg
three times weekly (days 35–60; 12 doses). During the last
week of IFNb-1a treatment, therapy with cladribine tablets
(50–100 mg in total) was coadministered for 5 consecutive
days (days 56–60). Blood samples for PK analysis were
taken pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36
and 48 h post-dose at the following times: at the end of the
initial treatment course of cladribine tablets (days 4–7);
after 2 weeks of IFNb-1a 44 lg (days 45–48); and after the
last concomitant administration of cladribine tablets and
IFNb-1a (days 59–62).
Study 25643 (CLARITY) was a phase III, double-blind,
placebo-controlled, 96-week study evaluating the safety
and efficacy of cladribine tablets in patients with relapsing–
remitting MS [3]. Patients were randomly assigned (1:1:1
ratio) to receive one of two cumulative doses of cladribine
tablets or placebo. Depending on their actual body weight,
patients took one or two cladribine 10 mg tablets (or
matching placebo) per day over 4–5 days in either (1)
weeks 1 and 5 of years 1 and 2, or (2) weeks 1, 5, 9, and 13
of year 1, followed by weeks 1 and 5 of year 2, for a
cumulative dose of 3.5 and 5.25 mg/kg, respectively [3].
Detailed information on the dosing of cladribine tablets in
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the CLARITY study is provided in electronic supplemen-
tary Tables 1 and 2. Samples from 125 patients were
available for population analysis.
2.2 Bioanalytical Analysis
Bioanalytical methods were developed and validated to
support the clinical program for cladribine, as described
briefly below. CdA and CAde were quantified by liquid
chromatography-tandem mass spectrometry (LC-MSMS)
methods, validated for human plasma and urine. The lower
limit of quantification (LLOQ) for both CdA and CAde
was 100 pg/mL, and precision and accuracy of quality
controls were assessed for the range of 100–45,000 pg/mL
of CdA and CAde. Intra- and interbatch precision was
below 7.5%. Furthermore, intrabatch accuracy of quality
controls was between -8.7 and 5.8%, and -1.3 and 4.8%
for CdA and CAde, respectively, and interbatch accuracy
of quality controls was included in the range -1.7–1.6%,
and -0.1–3.3% for CdA and CAde, respectively. No
interfering chromatographic peaks were observed in blank
plasma samples for CdA, CAde and the internal standards.
2.3 Population Pharmacokinetic (PK) Analysis
2.3.1 Structural Model Development
The model-building procedure included the development
of five key models/steps described below and summarized
in Table 1.
1. Development of a model for CdA and CAde, both in
plasma and urine, after intravenous administration of
CdA. Data used for this step were from study 25803
(after intravenous administration only)—Model I.
2. An extension of Model I with the absorption model in
the fasted state. Data were extended with the oral
administration data from study 25803 (CdA and CAde,
both in plasma and urine)—Model II.
3. An extension of Model II with the absorption model in
the fed state. Data were extended with the data from
study 26127—Model III.
4. An extension of Model III with the model for multiple
dosing of CdA and its interaction with IFNb-1a. Data
were extended with the data from study 26486—
Model IV.
5. Extension of Model IV with the data from study
25643—Model V.
PK modeling began with a three-compartment model
with first-order (linear) elimination and first-order absorp-
tion for oral administration. More complex PK models with
respect to absorption and disposition were evaluated for
both CdA and CAde.
2.3.2 Statistical Model Development
Additive, log-additive, proportional and combined-error
models were explored for residual variability. Between-
patient variability in residual error was evaluated, and
additive and/or exponential error models were explored for
between-patient variability in the model parameters. A
diagonal X-structure was initially employed and the
inclusion of off-diagonal elements was investigated.
2.3.3 Covariate Model Development
The identification of covariates was undertaken using
‘Stepwise Covariate Model-Building’ using Perl-speaks
NONMEM (PsN; version 2.3.2 and higher) [6]. This
method involved stepwise testing of linear and non-linear
relationships in a forwards inclusion (change in objective
function value [DOFV] of 6.63; p\ 0.01 for 1 degree of
freedom [DF]) and backwards exclusion (DOFV of 10.83;
p\ 0.001 for 1 DF) procedure [7]. The resultant final
model contained covariates that met the predefined statis-
tical criteria. In addition, covariates would only be retained
on the basis of their relevance, in view of the purpose of the
model. The covariates tested were concomitant IFNb-1a
administration (16 yes/157 no), food state (16 fed/16 fas-
ted/141 unknown), and markers of renal function, i.e.
creatinine clearance [CLCR], based on the Cockcroft–Gault
equation, sex, age and body weight.
2.3.4 Modeling Methodology and Software
The population PK analysis was performed using the non-
linear mixed effects modeling approach using NONMEM
(version VI and higher; Icon Development Solutions,
Hanover, MD, USA) [8]. The R-based version of Xpose
(version 4.0 and higher) was used to produce standard
goodness-of-fit plots [6]. Perl (version 5.8.8; http://www.
perl.org) and PsN were used for model evaluation and
automatic covariate model-building [6].
Table 1 Overview of the key modeling steps
Model No. of
subjects
No. of
samples
Studies
I 16 397 25803 (IV data)
II 16 848 25803 (IV and oral data)
III 32 1264 25803, 26127
IV 48 1683 25803, 26127, 26486
V 173 2619 25803, 26127, 26486, 25643
IV intravenous
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The NONMEM estimation methods used were first-
order conditional (FOCE) and FOCE with interaction
(FOCEI). The stability of NONMEM models was assessed
on the basis of acceptable basic goodness-of-fit plots,
number of significant digits C3 for all estimated parame-
ters, successful covariance step, estimates of typical patient
parameters (O–’s) not close to a boundary, and stability
check performed for a selected basic model (the model
finds the global minimum when the initial values are
altered in each direction [i.e. each parameter, one at a time]
by a large factor [10 in this analysis]). Model selection was
based on the comparison of full versus reduced models
using the log-likelihood criterion (the difference in the
minimum OFV between hierarchical models was assumed
to be Chi-square distributed with degrees of freedom equal
to the difference in the number of parameters between
models), goodness-of-fit plots (e.g. relevant residuals
against time randomly distributed around zero), and sci-
entific plausibility of the model.
2.3.5 Model Evaluation
To evaluate whether the estimated fixed- and random-ef-
fect parameters adequately describe data, 1000 Monte
Carlo simulation replicates of the original dataset were
generated using each of the five key population PK models
(Model I through Model V). The data were plotted versus
time along with the summary statistics computed from the
simulated data with 5th, 50th, and 95th percentiles
including uncertainty. The coincidence between the origi-
nal data and simulated data demonstrated the predictive
ability of fixed effects parameters in the final model. The
visual predictive check was stratified on variables of
interest, such as route of administration, food state and
coadministration with IFNb-1a.
A stratified non-parametric bootstrap procedure was
performed to assess the uncertainty and stability of all key
models. Confidence intervals were calculated from the
successfully converged runs, and a large, non-parametric
bootstrap (n = 1000) was performed for Models I and II
only due to long run times. A shorter non-parametric
bootstrap including 30 and 100 samples was performed to
assess standard errors for Models IV and V, respectively.
3 Results
3.1 Data
A summary of the studies included in this analysis is
provided in Table 2. PK profiles from a total of 173
patients were used in this analysis and a summary of the
study demographics is shown in Table 3. The original
dataset contained 4790 concentration–time records; 45% of
records were excluded for various reasons, such as being
below the limit of quantification (BLQ) and missing sam-
pling times, leaving 2619 concentration records for popu-
lation analysis. Most of the excluded data (96.5%) were
BLQ records, coming mostly from two studies: approxi-
mately one-third of the BQL samples from study 25803
with an extended follow-up period (up to 120 h), and
approximately two-thirds of the BQL samples from study
25643, where approximately half the samples were col-
lected before the administration of the CdA dose.
3.2 Population PK Model
3.2.1 Structural Model Development
Model I A three-compartment model best described the PK
of CdA after intravenous administration, and a one-com-
partment model best described the PK of the main CdA
metabolite, CAde. Available urine data enabled estimation
of renal clearance (CLR) for both CdA and CAde. For CdA,
CLR was implemented as a linear function of CLCR, while
renal elimination of the metabolite was best described with
a saturable model. Separate non-CLR (CLNR) and CLR for
both the parent drug and metabolite could be estimated.
The fraction of metabolized drug could be assessed as
CLNR/total clearance = 0.536. Renal elimination of CdA
Table 2 Summary of the studies included in the population PK analysis
Study Phase na No. of CdA samplesb No. of CAde samplesb Treatment: administration and dose (cumulative)
Plasma Urine Plasma Urine
25803 I 16 404 166 189 89 CdA: 3 mg IV infusion/10 mg single oral doses
26127 I 16 416 – – – CdA: 10 mg single oral doses
26486 I 16 419 – – – CdA: 1.75 mg/kg orally over 8 weeks ? IFNb-1a
25643 III 125 470 – 466 – CdA: 3.5 or 5.25 mg/kg orally over 2 years
PK pharmacokinetic, CdA cladribine, CAde 2-chloroadenine, IV intravenous, IFN interferon, RRMS relapsing-remitting multiple sclerosis
a Number of CdA-treated RRMS patients included in the population PK analysis
b Total number of samples available for the population PK analysis
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accounted for approximately 50% of total elimination,
while renal elimination of the metabolite was minor.
Metabolite profiles were well described, as indicated by the
low residual variability (13.4%), even though no separate
interindividual variability was estimated in the metabolite
disposition parameters.
Model II A first-order absorption model was sufficient to
describe the absorption of CdA in the fasted state. The
introduction of absorption delay models, such as a lag-time
model and a transit-compartment model, offered some
improvement in the fit. However, the observed delay could
be assigned to only a few individuals and therefore it was
not kept in the model. Bioavailability was estimated to be
45.5%.
Model III Inclusion of the data from the fed state, with
the aim of assessing the effect of food on absorption
parameters, required elaboration of the absorption model to
describe the effect of food on the absorption delay. The
transit-compartment model best described the absorption
delay in the data from the fed state. This model offered an
improvement compared with first-order absorption with a
lag time. Mean transit time was estimated to be 1.04 h, and
the number of transit compartments was estimated to be
2.44. Bioavailability decreased with food by approximately
14%.
Model IV Data from the multiple-dosing schedule (study
26486) did not contain information on food state and
therefore absorption parameters were modeled separately.
A potential effect of IFNb-1a coadministration on CdA
bioavailability and CLNR was tested. The bioavailability of
CdA in study 26486 was generally lower compared with
other studies; however, no significant differences in
bioavailability were found between CdA administered
alone and CdA administered with IFNb-1a. IFNb-1a
coadministration led to an increase in CLNR of CdA of
approximately 22%, which was statistically significant
(p\ 0.05) and associated with a slight improvement in
predictive checks.
Model V The addition of phase III data only required the
addition of a lag time, which improved the fit during the
absorption phase. Overall, with the addition of phase III
data, parameters changed very little compared with the
parameters from the final phase I model. Due to sparse
sampling at late time points, the phase III data were lacking
information relating to CLR; however, due to the presence
of metabolite data, they supported good estimation of
CLNR and bioavailability. Good correspondence between
phases I and III was observed for almost all parameters,
although some changes in the rate of absorption were
observed. The population parameter point estimates and
their uncertainty, assessed via non-parametric bootstrap
(n = 100), are shown in Table 4, and the structure of the
final model is shown in Fig. 1.
The final model was used to generate cladribine profiles
following 5 days of cladribine treatment (dose = 10 mg)
for a typical patient with normal renal function. CdA
concentrations were then predicted using three different
values of CLCR, mimicking 3 degrees of severity of renal
impairment, by incorporating those values into the devel-
oped model. The predicted decrease in total clearance was
19%, 30% and 40% for patients with mild (CLCR = 65 ml/
min), moderate (CLCR = 40 ml/min) and severe
(CLCR = 20 ml/min) renal impairment, respectively.
3.2.2 Covariate Model Development
Covariate analysis revealed no significant influence of
demographic covariates (body weight, age and sex) on PK
parameters, in addition to their impact on renal function
mediated though CLCR. Additional investigation of indi-
vidual predicted CLNR against aspartate aminotransferase
(AST), alanine aminotransferase (ALT) and bilirubin did
Table 3 Summary of the
patient demographics
Variable Study 25803 Study 26127 Study 26486 Study 25643 Overall
Age, years
Median 36 29.5 48.5 40 40
Range 27–54 20–58 32–54 19–65 19–65
Body weight, kg
Median 77.5 70.5 69.5 68.9 69.2
Range 51–99 54–97 50–93 48.5–116.1 48.5–116.1
Sex [n (%)]
Male 10 (62.5) 4 (25) 6 (37.5) 39 (31.2) 59 (34.1)
Female 6 (37.5) 12 (75) 10 (62.5) 86 (68.8) 114 (65.9)
CLCR, mL/min
Median 109.2 121.2 103.7 105.8 107.9
Range 70.2–139.8 94.9–150.8 67.1–164.9 49.6–244.4 49.6–244.4
CLCR creatinine clearance
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Table 4 Population PK
parameter estimates from the
final model
Parameter Final model RSE, %a
Cladribine
CLR coefficient
b (typical patient with CLCR = 6.31), L/h
c 3.52 (22.2) 9.26
CLNR, L/h 23.4 9.58
Central volume, L 44.0 22.77
Intercompartmental Q3, L/h 14.3 7.73
Intercompartmental Q4, L/h 53.7 19.06
Peripheral volume V3, L 347 6.07
Peripheral volume V4, L 89.5 7.97
Absorption rate constant, h-1 1.08 21.14
Absorption rate constant (unknown/fed state), h-1 1.03 11.62
Bioavailability 0.456 7.03
Bioavailability (unknown/fed state) 0.4 5.28
Lag time for phase III, h 0.319 12.41
Mean transit time (fed state), h 0.910 11.03
Number of transit compartments 2.24 27.15
Fold increase in CLNR in the presence of IFNb-1a 1.21 8.46
BSVCLNR 0.00574 64.41
BSVV 0.209 72.51
BSVQ3,Q4,V3,V4 0.0365 28.47
BSVKa 0.102 62.53
BSVF
d 0.223 19.13
BSVResidual variability 0.159 16.66
RUV plasma (intravenous), % 20.0 11.21
RUV plasma (oral), % 34.7 16.19
RUV plasma (oral; studies 26127, 26486), % 22.8 5.84
RUV plasma (oral; study 25643), % 35.3 6.74
RUV urine, % 87.1 10.89
2-Chloroadenine
CLR
e (Vmax), lg/h 0.00280 25.53
CLR
e (Km), ng/L 0.0114 58.14
Apparent hepatic CL, L/hf 653 10.64
Apparent central volume V, Lf 365 13.27
RUV plasma, % 34.3 19.64
RUV plasma (study 25643), % 31.8 76.38
RUV urine, % 104 14.32
BSV between subject variability for the random-effects distribution of the parameter, CL clearance, CLCR
creatinine clearance, CLNR non-renal clearance, CLR renal clearance, F bioavailability, IFN interferon, Ka
absorption rate constant, Km metabolite concentration at which the half maximal renal clearance rate is
achieved, PK pharmacokinetic, Q3 intercompartment clearance between the central and first peripheral
compartment, Q4 intercompartment clearance between the central and second peripheral compartment,
RSE relative standard error, RUV residual unexplained variability (proportional component), V volume of
distribution, V3 peripheral one-compartment volume of distribution, V4 peripheral two-compartment vol-
ume of distribution, Vmax maximal CLR rate for metabolite
a RSEs from bootstrap (n = 100) in NONMEM
b Scaled parameter to be dimensionless. Original parameter estimated in NONMEM run had units of L/h
c CLR, L/h = coefficient 9 CLCR, L/h
d Variance on a logit scale
e CLR = Vmax 9 CM/(KM ? CM); saturable elimination, where CM = metabolite concentration
f Corrected for the fraction metabolized to 2-chloroadenine
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not show any association between liver function markers
and CLNR.
3.2.3 Model Evaluation
The final model was evaluated by a visual predictive check
stratified on variables of interest, such as route of admin-
istration, food state and coadministration with IFNb-1a
(Figs. 2, 3, 4). The stratified non-parametric bootstrap
(n = 30–1000) was performed for all key models in order
to compute relative standard errors (RSE) for parameters.
4 Discussion
This analysis characterized the population PK of both CdA
and CAde following oral and intravenous administration of
CdA in patients with relapsing–remitting MS. The final
population PK model provided a good description of the
PK data of CdA in patients with MS. Goodness-of-fit cri-
teria revealed that the final model was consistent with the
observed data and no systematic bias remained. The model
evaluation results provided evidence that both the fixed and
random effect components of the final model were reflec-
tive of the observed data.
The PK data were described reasonably well using a
three-compartment PK model, which is consistent with
previous findings [4]. Availability of the urine data enabled
separation of the CLR and CLNR, and the typical population
parameter estimates from the final model for these two
elimination routes were CLR = 22.2 L/h and
CLNR = 23.4 L/h, indicating that both elimination path-
ways are equally represented. The previous population PK
analysis of CdA reported a value for total clearance of
39.3 L/h [4]; however, that analysis was carried out in
terminally ill cancer patients, who are likely to have
decreased function of vital organs and therefore lower
clearance values. Once the differences in the mean CLCR
between two populations are taken into account (4.86 L/h
in oncology patients compared with 6.31 L/h in the MS
population), the estimates of clearance become comparable
(39.3 vs. 40.5 L/h). Moreover, the previous analysis was a
retrospective analysis where the data were collected over
long time periods and using different bioanalytical meth-
ods, which may not provide fully comparable results. CLR
appeared to be higher than the glomerular filtration rate,
indicating that other mechanisms, such as active secretion,
are involved in CdA renal elimination, which is also con-
sistent with previous reports [9].
Bioavailability of CdA after oral administration was
45.6%, which is consistent with previous findings [10, 11].
Coadministration of CdA with food appeared to decrease
bioavailability to 40.5%, which is not expected to have a
clinically meaningful impact. In addition, food also
appeared to delay absorption.
Coadministration of CdA with IFNb-1a appeared to
have an effect on CdA clearance, which increased CLNR
by 21%, resulting in an increase of total clearance by
approximately 11.1%. However, although the modeling
pointed to this effect on CLNR, it could also have been
modeled on its bioavailability. Given the data available, it
was not really possible to discriminate between the two.
Furthermore, the observed effect could also be due to a
period effect or interoccasion variability; however, these
effects were confounded (owing to the study design) and
further elaboration could not be supported with the
available data. PK profiles of patients receiving CdA
alone or coadministered with pantoprazole were also
evaluated and no clinically relevant drug–drug interaction
was found.
Covariates included in the model were fasted/fed state
on absorption parameters, IFNb-1a effect on CLNR, and
CLCR on CLR of CdA. Sex, age and body weight have also
been investigated and were not associated with the PK of
CdA (except for their impact on renal function mediated
though CLCR). A graphical investigation of individual
predicted CLNR against AST, ALT and bilirubin did not
show any association between liver function markers and
CLNR, and the previous population analysis of CdA in
cancer patients also revealed no significant covariate effect
[4].
The PK of the main CdA metabolite, CAde, were well
described by a one-compartment model. Apparent CLNR
Fig. 1 Schematic representation of the final model.CdA cladribine,Ka
absorption rate constant, Ktr transfer rate constant, F bioavailability,
TC2 second transit compartment, TCn: nth transit compartment, per 1
first peripheral compartment, per 2 second peripheral compartment, CL
clearance, CRCL creatinine clearance, CAde 2-chloroadenine
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and volume of distribution for CAde were found to be
653 L/h and 365 L, respectively. The availability of urine
data for CAde enabled separation of the renal and non-
renal elimination pathways for CAde. Renal elimination
appeared to be saturable and to represent a minor
elimination pathway. The visual predictive check of Model
II indicated a possible second compartment for CAde;
however, this further extension of the metabolite model
was not supported by the limited data. Furthermore, the
indication of a second compartment could be spurious,
driven by sporadic visible observations above the quan-
tification limit (most of the metabolite observations were
below the LLOQ at these late time points).
The estimated variability in most CdA PK parameters
was modest. Moreover, the rather low variability in
bioavailability demonstrated the consistent performance of
the tablet formulation with regard to drug release and
dissolution. Residual variability of urinary data was rather
high (close to 90%). Urinary data are often more erratic
than plasma, and, in these profiles, some inconsistent pat-
terns were observed, which may have made it difficult to
separate the variability sources. The estimated variability
in CLR is low, and, in the final model, almost all variability
in the urinary output is attributed to residual error.
5 Conclusions
The PK of CdA and its main metabolite, CAde, in patients
with MS were described after both intravenous and oral
administration of CdA, with estimation of CLR and CLNR
for both compounds. Food appeared to delay CdA
absorption and to slightly decrease the extent of absorption.
Coadministration of IFNb-1a slightly increased the CLNR
of CdA, without a significant impact on CdA exposure,
owing to the evenly split clearance between non-renal and
Fig. 3 Visual predictive checks for CdA and CAde in urine of
intravenously and orally administered CdA. Light blue shaded area
indicates simulated median with uncertainty; pink shaded area
indicates simulated 5th and 95th percentiles with uncertainty; solid
blue line indicates observed median; dashed blue line indicates
observed 5th and 95th percentiles. a Based on 83 samples from 16
subjects; b based on 83 samples from 16 subjects; c based on 40
samples from 16 subjects; d based on 49 samples from 16 subjects.
CdA cladribine, CAde 2-chloroadenine, IV intravenous
Fig. 2 Visual predictive checks
for CdA and CAde in plasma of
intravenously and orally
administered CdA. Light blue
shaded area indicates simulated
median with uncertainty; pink
shaded area indicates simulated
5th and 95th percentiles with
uncertainty; solid blue line
indicates observed median;
dashed blue line indicates
observed 5th and 95th
percentiles. a Based on 193
samples from 16 subjects;
b based on 211 samples from 16
subjects; c based on 470
samples from 125 subjects;
d based on 81 samples from 16
subjects; e based on 108
samples from 16 subjects; and
f based on 466 samples from
125 subjects. CdA cladribine,
md multiple dosing, CAde
2-chloroadenine, IV intravenous
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renal components. The proposed model explained the PK
of CdA in great detail thanks to the informative design of
several clinical studies.
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